ID   Marimo
AC   CVCL_6992
DR   cancercelllines; CVCL_6992
DR   Cosmic; 787448
DR   Cosmic; 975266
DR   Cosmic; 1012083
DR   Cosmic; 1281324
DR   Cosmic; 1465956
DR   Cosmic; 1465959
DR   Cosmic; 2306195
DR   Wikidata; Q54904030
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=9406575;
RX   PubMed=16408098;
RX   PubMed=21552520;
RX   PubMed=25249012;
RX   PubMed=30115971;
CC   Characteristics: This cell line is independent of the CALR-MPL-JAK2-STAT5 pathway.
CC   Doubling time: 25-28 hours (PubMed=9406575).
CC   Sequence variation: Mutation; HGNC; 1455; CALR; Simple; p.Leu367Metfs*43 (c.1099_1159del61); Zygosity=Heterozygous (PubMed=25249012; PubMed=30115971).
CC   Sequence variation: Mutation; HGNC; 7217; MPL; Simple; p.Ser505Asn (c.1514G>A); ClinVar=VCV000014163; Zygosity=Heterozygous (PubMed=30115971).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=30115971).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Tyr (c.404G>A); ClinVar=VCV000141762; Zygosity=Homozygous (PubMed=30115971).
CC   Omics: Deep quantitative phosphoproteome analysis.
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C8252; Therapy-related acute myeloid leukemia
DI   ORDO; Orphanet_86846; Therapy related acute myeloid leukemia and myelodysplastic syndrome
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   68Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 19
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
RX   PubMed=9406575; DOI=10.1016/S0165-4608(97)00017-4;
RA   Yoshida H., Kondo M., Ichihashi T., Hashimoto N., Inazawa J., Ohno R.,
RA   Naoe T.;
RT   "A novel myeloid cell line, Marimo, derived from therapy-related acute
RT   myeloid leukemia during treatment of essential thrombocythemia:
RT   consistent chromosomal abnormalities and temporary C-MYC gene
RT   amplification.";
RL   Cancer Genet. Cytogenet. 100:21-24(1998).
RX   PubMed=16408098; DOI=10.1038/sj.leu.2404081;
RA   Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.;
RT   "JAK2 V617F tyrosine kinase mutation in cell lines derived from
RT   myeloproliferative disorders.";
RL   Leukemia 20:471-476(2006).
RX   PubMed=21552520; DOI=10.1371/journal.pone.0019169;
RA   Gu T.-L., Nardone J., Wang Y., Loriaux M., Villen J., Beausoleil S.A.,
RA   Tucker M., Kornhauser J.M., Ren J.-M., MacNeill J., Gygi S.P.,
RA   Druker B.J., Heinrich M.C., Rush J., Polakiewicz R.D.;
RT   "Survey of activated FLT3 signaling in leukemia.";
RL   PLoS ONE 6:E19169-E19169(2011).
RX   PubMed=25249012; DOI=10.1038/leu.2014.285;
RA   Kollmann K., Nangalia J., Warsch W., Quentmeier H., Bench A., Boyd E.,
RA   Scott M., Drexler H.G., Green A.R.;
RT   "MARIMO cells harbor a CALR mutation but are not dependent on
RT   JAK2/STAT5 signaling.";
RL   Leukemia 29:494-497(2015).
RX   PubMed=30115971; DOI=10.1038/s41375-018-0234-6;
RA   Han L.-J., Czech J., Maurer A., Brummendorf T.H., Chatain N.,
RA   Koschmieder S.;
RT   "Mutant NRAS Q61K is responsible for MAPK pathway activation in the
RT   MARIMO cell line and renders these cells independent of the
RT   CALR-MPL-JAK2-STAT5 pathway.";
RL   Leukemia 32:2087-2090(2018).